Literature DB >> 30109001

Identification of potent catalytic inhibitors of human DNA topoisomerase II by structure-based virtual screening.

Guoqiang Dong1, Ying Wu1, Ying Sun2, Na Liu1, Shanchao Wu1, Wannian Zhang1, Chunquan Sheng1.   

Abstract

Human DNA topoisomerase II (Top2) is a promising target for cancer treatment. To overcome the limitations of known Top2 inhibitors, novel Top2 catalytic inhibitors with new scaffolds were identified by structure-based virtual screening. In particular, compound 8 showed good in vitro antiproliferative activity with a broad spectrum. Top2-mediated cleavage assay and molecular modeling rationalized the mode of action. The new Top2 inhibitors are considered as good starting points for further hit-to-lead optimization in anticancer drug discovery.

Entities:  

Year:  2018        PMID: 30109001      PMCID: PMC6071756          DOI: 10.1039/c8md00219c

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  25 in total

Review 1.  Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases.

Authors:  Kevin D Corbett; James M Berger
Journal:  Annu Rev Biophys Biomol Struct       Date:  2004

2.  Pose prediction and virtual screening performance of GOLD scoring functions in a standardized test.

Authors:  John W Liebeschuetz; Jason C Cole; Oliver Korb
Journal:  J Comput Aided Mol Des       Date:  2012-02-28       Impact factor: 3.686

3.  Discovery of a new class of catalytic topoisomerase II inhibitors targeting the ATP-binding site by structure based design. Part I.

Authors:  Pascal Furet; Joseph Schoepfer; Thomas Radimerski; Patrick Chène
Journal:  Bioorg Med Chem Lett       Date:  2009-06-13       Impact factor: 2.823

4.  Development and validation of a genetic algorithm for flexible docking.

Authors:  G Jones; P Willett; R C Glen; A R Leach; R Taylor
Journal:  J Mol Biol       Date:  1997-04-04       Impact factor: 5.469

5.  Discovery of mono- and disubstituted 1H-pyrazolo[3,4]pyrimidines and 9H-purines as catalytic inhibitors of human DNA topoisomerase IIα.

Authors:  Barbara Pogorelčnik; Matjaž Brvar; Bojana Žegura; Metka Filipič; Tom Solmajer; Andrej Perdih
Journal:  ChemMedChem       Date:  2014-12-17       Impact factor: 3.466

6.  Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents.

Authors:  Guoqiang Dong; Chunquan Sheng; Shengzheng Wang; Zhenyuan Miao; Jianzhong Yao; Wannian Zhang
Journal:  J Med Chem       Date:  2010-11-11       Impact factor: 7.446

Review 7.  Recent advances in protection against doxorubicin-induced toxicity.

Authors:  R Injac; B Strukelj
Journal:  Technol Cancer Res Treat       Date:  2008-12

Review 8.  Catalytic topoisomerase II inhibitors in cancer therapy.

Authors:  Annette K Larsen; Alexandre E Escargueil; Andrzej Skladanowski
Journal:  Pharmacol Ther       Date:  2003-08       Impact factor: 12.310

Review 9.  DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition.

Authors:  Yves Pommier
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

Review 10.  DNA topoisomerase II, genotoxicity, and cancer.

Authors:  A Kathleen McClendon; Neil Osheroff
Journal:  Mutat Res       Date:  2007-07-03       Impact factor: 2.433

View more
  2 in total

1.  Determination of anticancer potential of a novel pharmacologically active thiosemicarbazone derivative against colorectal cancer cell lines.

Authors:  Azmat Ali Khan; Rehan Ahmad; Amer M Alanazi; Nawaf Alsaif; Maha Abdullah; Tanveer A Wani; Mashooq A Bhat
Journal:  Saudi Pharm J       Date:  2022-03-31       Impact factor: 4.562

2.  Smoothed Potential MD Simulations for Dissociation Kinetics of Etoposide To Unravel Isoform Specificity in Targeting Human Topoisomerase II.

Authors:  Jissy A Kuriappan; Neil Osheroff; Marco De Vivo
Journal:  J Chem Inf Model       Date:  2019-09-09       Impact factor: 4.956

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.